How Maze Therapeutics Navigated Genetics-based Drug Discovery. By co-founder and former CSO Eric Green. (Sub. Req.) timmermanreport.com/2025/02/how-ma…

This weekend, we were honored to attend the ALS ONE Snowball Gala. The annual Snowball supports critical #ALS research & care for patients & their loved ones. We had an inspiring evening celebrating the strength of those impacted by this disease.

We're excited to begin a new partnership with Unlearn.AI to utilize their Digital Twin Generator for #ALS & the Unlearn Platform as we plan our upcoming Phase 1/2 clinical trial in ALS. Read more from CEO Eric Green below & here: businesswire.com/news/home/2025…

Trace CMO Irina Antonijevic looks forward to sharing experience from three decades of working in psychiatry and neurology drug development during the #CMO360Summit Rare Disease roundtable next week. Learn more about the summit and register to attend here. cmosummit360.com

May is #ALSAwarenessMonth. 1 in every 400 people worldwide will be diagnosed with ALS their lifetime. This month, we join our community in raising awareness of both the devastating effects of this debilitating disease & the need for new treatment options for those living with it.

Trace scientists Shila Mekhoubad and Ryan Morrie look forward to sharing insight into our work on UNC13A expression and its relation to ALS during the Target ALS annual meeting this week. Learn more: targetals.org/research/annua…

This week, Terry Fang will join other #ALS industry experts at the #ALSDrugDevelopment Summit! Find her during Day 2 on the Clinical & Translational Utility Track. For more details, check out the ALS Drug Development Summit agenda. als-drug-development.com/whats-on/full-…

CBO/CSO Nick Mordwinkin will join University of California for their Reinvigorating Innovation in #ALS symposium tomorrow! This will be an interactive event, maximizing the UC system-wide ALS expertise with physicians, biomedical researchers, engineers & scientists. innovation.ucsf.edu/reinvigorating…

At Trace, we think every person should have access to proper treatment for their disease, including those with #ALS. On #LouGehrigDay, we join No Patient Left Behind in their mission to make medicines affordable for every patient in America. Eric Green joins fellow biotech leaders to share more.

"Precision separates expert from novice, health from disease and success from failure in drug development." CEO Eric Green sat down with new Harvard M.D.-Ph.D. grad Dylan Neel, MD PhD to discuss our vision for reshaping the #ALS and neurodegenerative disease treatment landscape. ⬇️

CEO Eric Green & CBO/CSO @nmordwinkin will join the #neuroscience community at the H.C. Wainwright Neuro Perspectives conference next week. Join us at this hybrid event: hcwevents.com/neuro-perspect…

CBO/CSO @nmordwinkin will be on the East Coast for #BIO2025 this week! We look forward to the opportunity to connect with #biotech and #neuro peers, old and new. See you soon.

Fatal neurodegenerative diseases like ALS don't discriminate. Tomorrow on #GlobalALSAwarenessDay we join our peers in advocating for better research, advanced therapies & ultimately, hope for those affected by this diagnosis. Learn more from ALS/MND Alliance. #ALSMNDWithoutBorders

Happy #Pride! This June, we proudly celebrate Pride Month and stand with the LGBTQ+ community. At Trace, we believe that diversity makes us stronger, and we are committed to fostering a workplace and broader community where everyone feels seen, valued and respected. 🌈

Our employees and their families have been all over the map this summer! From exploring Newport to hiking in Colorado and relaxing by the lake in Tahoe, an opportunity to recharge was well-deserved for our dedicated team. Check out some of our favorite shots from coast to coast.

Sometimes, committing to impacting those with #ALS means getting ice water dumped on us. We recently partnered with ALS Network to sponsor #SplashToCureALS. CEO Eric Green, COO Megan Baierlein & CBO/CSO Nick Mordwinkin helped to raise awareness and drop their body temperatures. 🧊

This week, we are excited to present a poster on preclinical data from our lead ASO development candidate, TRCN-1023, and the Phase 1/2 clinical trial outline at #ALSNexus. The poster will be presented by CMO Irina Antonijevic on Wednesday evening's poster session, 4-6:30PM CDT.

CMO Irina Antonijevic looks forward to joining ALS TDI & Alexandria Real Estate Center for Life Science during Last Nerve, an event focused on innovation in #ALS research through the lens of advocate and author Mindy Uhrlaub's new book. Details here. events.are.com/lastnerve20252

SVP, Development Sciences, Marjie Hard, will share our recent work in Advancing a Splice-Modulating ASO Restoring UNC13A protein for #ALS during this week's Oligonucleotides for CNS Summit in Boston. Join us for her session on Friday! oligonucleotides-cns.com/whats-on/full-…

Today, we heard from John & Nancy Frates, parents of Pete Frates, who was diagnosed with #ALS in 2012 & led the ALS Ice Bucket Challenge, a viral movement that forever changed the fight against ALS. They continue support the fight & honor Pete's legacy through the Peter Frates ALS Foundation.